Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419004 | 0.81 | KHK (0.46) | KHKTRPV4ADRB2ADRB1CYP11B1 | |
| SCHEMBL10474259 | 0.76 | KHK (0.42) | KHKTRPV4ADRB2ADRB1CYP11B1 | |
| SCHEMBL26697124 | 0.72 | KHK (0.42) | KHKTRPV4ADRB2ADRB1CYP11B1 | |
| SCHEMBL19769015 | 0.71 | ADRB2 (0.41) | KHKTRPV4ADRB2ADRB1CYP11B1 | |
| SCHEMBL25991361 | 0.69 | TRPV4 (0.45) | KHKTRPV4CYP11B1CYP11B2 | |
| SCHEMBL404723 | 0.69 | ADRB2 (0.45) | KHKTRPV4ADRB2ADRB1CYP11B1 | |
| SCHEMBL809090 | 0.69 | TRPV4 (0.48) | KHKTRPV4CYP11B1CYP11B2 | |
| SCHEMBL31588414 | 0.69 | TRPV4 (0.48) | KHKTRPV4CYP11B1CYP11B2 | |
| SCHEMBL9889145 | 0.69 | CA1 (0.33) | — | |
| SCHEMBL25436881 | 0.69 | TRPV4 (0.43) | KHKTRPV4CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875839-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | KHK 2768/4885TRPV4 1233/4885ADRB2 264/4885 |
| US-10875839-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | KHK 2768/4885TRPV4 1233/4885ADRB2 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.